Literature DB >> 15917550

Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.

Nataliya Korzheva1, Todd A Davies, Raul Goldschmidt.   

Abstract

Resistance of Streptococcus pneumoniae to fluoroquinolones is caused predominantly by amino acid substitutions at positions Ser79 of ParC and Ser81 of GyrA to either Phe or Tyr encoded in the quinolone resistance-determining regions of the parC topoisomerase IV and gyrA DNA gyrase genes. Analysis of highly resistant clinical isolates identified novel second-step substitutions, Ser79Leu (ParC) and Ser81Ile (GyrA). To determine contributions of these new mutations to fluoroquinolone resistance either alone or in combination with other Ser79/81 alleles, the substitutions Ser79Leu/Phe/Tyr in ParC and Ser81Ile/Phe/Tyr in GyrA were introduced into the R6 background, resulting in 15 isogenic strains. Their level of fluoroquinolone resistance was determined by susceptibility testing for ciprofloxacin, levofloxacin, moxifloxacin, gatifloxacin, gemifloxacin, garenoxacin, and norfloxacin. Leu79 and Ile81 alone as well as 79/81Phe/Tyr substitutions did not contribute significantly to resistance, with fluoroquinolone MICs increasing two- to fourfold compared to wild type for all agents tested. Fluoroquinolone MICs for double transformants ParC Ser79Phe/Tyr/Leu-GyrA Ser81Phe/Tyr were uniformly increased by 8- to 64-fold regardless of pairs of amino acid substitutions. However, combinations including Ile81 conferred two- to fourfold-higher levels of resistance than did combinations including any other Ser81 GyrA substitution, thus demonstrating the differential effects of diverse amino acid substitutions at particular hotspots on fluoroquinolone MICs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917550      PMCID: PMC1140505          DOI: 10.1128/AAC.49.6.2479-2486.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  53 in total

1.  Temporal regulation of topoisomerase IV activity in E. coli.

Authors:  Olivier Espeli; Cindy Levine; Heide Hassing; Kenneth J Marians
Journal:  Mol Cell       Date:  2003-01       Impact factor: 17.970

Review 2.  Untangling intracellular DNA topology.

Authors:  Olivier Espeli; Kenneth J Marians
Journal:  Mol Microbiol       Date:  2004-05       Impact factor: 3.501

3.  STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III.

Authors:  O T Avery; C M Macleod; M McCarty
Journal:  J Exp Med       Date:  1944-02-01       Impact factor: 14.307

4.  An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae.

Authors:  L S Håvarstein; G Coomaraswamy; D A Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

5.  Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

Authors:  X S Pan; L M Fisher
Journal:  J Bacteriol       Date:  1996-07       Impact factor: 3.490

6.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.

Authors:  X Zhao; C Xu; J Domagala; K Drlica
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

7.  Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.

Authors:  L M Weigel; G J Anderson; R R Facklam; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

8.  Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.

Authors:  X S Pan; G Yague; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.

Authors:  María Pérez-Vázquez; Federico Román; Belén Aracil; Rafael Cantón; José Campos
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

View more
  4 in total

1.  In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.

Authors:  Brian J Morrow; Wenping He; Karen M Amsler; Barbara D Foleno; Mark J Macielag; A Simon Lynch; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

2.  Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.

Authors:  Klaudia Kosowska-Shick; Kim Credito; Glenn A Pankuch; Gengrong Lin; Bülent Bozdogan; Pamela McGhee; Bonifacio Dewasse; Dong-Rack Choi; Jei Man Ryu; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.

Authors:  Samir N Patel; Roberto Melano; Allison McGeer; Karen Green; Donald E Low
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-01-18       Impact factor: 3.944

4.  Fluoroquinolone-resistant Streptococcus pneumoniae.

Authors:  Mathias W R Pletz; Randolph V Fugit; Lesley McGee; Jeffery J Glasheen; Darcie L Keller; Tobias Welte; Keith P Klugman
Journal:  Emerg Infect Dis       Date:  2006-09       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.